SafeHeal raises $7m

Early stage medtech dev SafeHeal said today it has raised $7.4 million (EU €6 million) in a Series A round of financing, with funds slated to support the clinical and regulatory market access and a commercial launch. The Paris-based company is developing the Colovac, a digestive anastomosis protection device designed to reduce complications and remove the need for ostomies in colectomy patients. The system consists of a minimally invasive, full reversible implant that remains in place for approximately two weeks, or until tissue repair is complete, before removal. “This investment enables us to execute our aggressive clinical and regulatory strategy, launch commercial operations once CE mark will be received and also continue investing in our R&D. We are currently recruiting patients in our First-in-Human clinical trial in France and are planning to extend the enrollment to hospitals in Germany, the UK and the US”, SafeHeal CEO Karl Blohm said in a prepared statement. Funding from the round, which was led by Sofinnova Partners, is slated to support the company’s clinical and regulatory market access program and a potential commercial launch. “We are excited to invest in SafeHeal and believe that their endoluminal bypass sheath is the most innovative disruption in the protection of colorectal anastomosis. This investment also demonstrates the power of our strategy allowing us to be present from incubation, with MD Start building companies from the...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News safeheal Source Type: news